Cancer Biology & Therapy

• 

  Publication Venue For

  • Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy..  18:101-105. 2017
  • Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.  10:135-143. 2010
  • Targeting cell surface F1F0 ATP synthase in cancer therapy.  7:1837-1839. 2008
  • Targeting cell surface F₁ F₀ ATP synthase in cancer therapy.  7:1837-1839. 2008
  • PPARgamma agonists follow an unknown TRAIL in lung cancer..  6:107-109. 2007
  • Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs..  5:1383-1389. 2006
  • Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity..  5:867-874. 2006
  • Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment..  5:635-642. 2006
  • The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration..  5:300-304. 2006
  • Using immunotherapy to target EGF in patients with NSCLC..  5:150-151. 2006
  • A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer..  4:1316-1317. 2005
  • New clues to the genetic basis of testicular cancer suggest dead end mutations.  4. 2005
  • EpCAM is an important suppressor of anti-tumor immunity [2].  4. 2005
  • Using phage peptides to detect protein differences between cancer and normal tissues.  3:1194-1195. 2004
  • Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis..  3:1045-1050. 2004
  • APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q..  3:960-964. 2004
  • Serum proteomics yield new biomarkers for ovarian cancer.  3:794-795. 2004
  • Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death..  3:296-301. 2004
  • Targeting aberrant signal transduction pathways in lung cancer..  3:147-155. 2004
  • Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer..  3:73-78. 2004
  • Dietary glycine inhibits angiogenesis during wound healing and tumor growth..  2:173-178. 2003
  • EpCAM: A new therapeutic target for an old cancer antigen..  2:320-326. 2003
  • Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells..  2:446-451. 2003
  • SU5416 delays wound healing through inhibition of TGF-beta 1 activation..  1:121-126. 2002